
Silence Therapeutics (SLN) Stock Forecast & Price Target
Silence Therapeutics (SLN) Analyst Ratings
Bulls say
Silence Therapeutics is attractive because divesiran has strong biological and clinical validation in polycythemia vera, with Phase 2 SANRECO data showing an 87.5% response rate versus 18.8% on placebo and Phase 1 durability including a median 287 days to first phlebotomy after the final dose. The Merck acquisition further validates the mRNAi GOLD platform, while the company’s roughly $300 million market cap appears modest relative to a 75% probability of success, especially given the dosing advantage of Q6W or Q12W versus weekly competitors and a potential benchmark from rusfertide’s $1 billion to $2.3 billion NPV. Its wholly owned pipeline in cardiovascular disease, hematology, and rare disease adds additional optionality, but the near-term thesis is most tightly anchored to divesiran’s ability to reduce phlebotomy burden, improve hematocrit control, and support a registrational path.
Bears say
Silence Therapeutics is facing a weakened investment case because the Lp(a)HORIZON Phase 3 miss removed the key external catalyst for zerlasiran and, in management’s own framing, shifted the story largely onto divesiran. The company then suffered a major valuation reset as zerlasiran was assigned 0% probability of success versus 60% prior, while the model also assumes $200 million annual capital raises from 2028E to 2031E, implying dilution and a total firm value of about $1.2 billion versus $4.5 billion previously. In addition, divesiran remains commercially and clinically challenged in a crowded PV market, where sapablursen is already ahead in Phase 3 and the downside case suggests the stock could trade near cash if efficacy disappoints.
This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Silence Therapeutics (SLN) Analyst Forecast & Price Prediction
Start investing in Silence Therapeutics (SLN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Silence Therapeutics (SLN) Forecast
Silence Therapeutics (SLN) Analyst Forecast & Price Prediction
Start investing in Silence Therapeutics (SLN)
Order type
Buy in
Order amount
Est. shares
0 shares